The Food and Drug Administration has granted accelerated approval to Replimune’s investigational oncolytic therapy RP1, which will be marketed under the name Tudriqev, for the treatment of advanced melanoma, according to reporting by STAT. The public portion of the article states the agency cleared the treatment and frames the decision as a significant regulatory win for Replimune following a protracted approval process.
The available reporting does not include the detailed clinical data that supported the approval, specific indications or patient populations described in the label, or the safety profile that accompanied the regulatory action. Those details were not reported in the accessible portion of the source.
STAT reports that an FDA advisory committee voted in favor of the treatment before the agency issued the approval. The advisers concluded there was a meaningful signal of efficacy and emphasized unmet needs among patients with advanced melanoma.
The article also notes that FDA staff had expressed concerns about the design and conduct of Replimune’s key trial. Despite those staff-level reservations, the external advisers ultimately recommended support for the therapy. The specific design issues, the nature of the conduct concerns, and any formal FDA staff analyses or memos were not detailed in the excerpt and therefore are not reported here.
The approval marks a reversal in a contentious regulatory trajectory: STAT’s headline and reporting indicate RP1 had been rejected twice previously. The piece characterizes the latest decision as capping a tumultuous saga for the biotech company.
The article does not provide the dates, reasons, or specific FDA actions associated with the earlier rejections, nor does it summarize how the company’s subsequent submissions changed from prior filings. Those particulars were not reported in the accessible portion of the source.
STAT states that Replimune had not disclosed Tudriqev’s price at the time of reporting. The piece frames the approval as a major win for the company and for patient advocates but does not include direct quotes from company executives, the FDA, patient groups, or treating physicians in the publicly available excerpt.
Because the article is presented as a STAT+ exclusive, much of the in-depth coverage appears behind a paywall. As a result, several important regulatory and clinical items are not reported in the accessible text, including:
These omissions reflect the limits of the publicly available portion of the source article rather than an absence of such information in regulatory or company filings.
STAT characterizes the approval as addressing an urgent need among patients with advanced melanoma and as a notable regulatory victory for Replimune after two prior rejections. The advisory panel’s endorsement despite staff concerns underscores a situation in which external experts judged the available evidence and patient need sufficient to support clearance under an accelerated pathway.
Clinicians and stakeholders seeking complete clinical and regulatory details — including trial efficacy and safety data, the approved patient population, confirmatory trial obligations, and pricing and access plans — will need to consult the FDA’s approval letter and label, Replimune’s public statements, and full STAT+ coverage. These documents and disclosures were not reported in the publicly available excerpt of the source article.
Note on source and reporting
This summary is derived from the STAT News article by Elaine Chen dated Aug. 6, 2026. The article is identified as a STAT+ exclusive and the publicly accessible portion supplied the facts summarized above. Where the source did not provide specific clinical, regulatory, or commercial details, this rewrite explicitly states that those details were not reported in the available text.